Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "Composition",
"id" : "568046",
"meta" : {
"versionId" : "2",
"lastUpdated" : "2026-05-30T17:31:51.733Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-report-section-04"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 568046</b></p><a name=\"568046\"> </a><a name=\"hc568046\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 2; Last updated: 2026-05-30 17:31:51+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-m11-report-section-04.html\">M11ReportSection04</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/568046\">https://fevir.net/resources/Composition/568046</a></p><p><b>identifier</b>: FEvIR Object Identifier/568046</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{http://loinc.org 35528-9}\">CeSHarP Report</span></p><p><b>category</b>: <span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C218533}\">section4-trial-design</span></p><p><b>date</b>: 2026-05-30 17:31:51+0000</p><p><b>author</b>: Brian S. Alper, MD, MSPH</p><p><b>title</b>: M11 Report Section 4 (Trial Design) for M11ResearchStudy Template</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Derived From</p><p><b>target</b>: <a href=\"ResearchStudy-568025.html\">M11ResearchStudy Template</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cite As</p><p><b>target</b>: </p><div><p>M11 Report Section 4 (Trial Design) for M11ResearchStudy Template [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 568046. Revised 2026-05-30. Available at: https://fevir.net/resources/Composition/568046. Computable resource at: https://fevir.net/resources/Composition/568046#json.</p>\n</div></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Composition/568046",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "568046",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "35528-9",
"display" : "Clinical trial protocol Clinical trial protocol"
}
],
"text" : "CeSHarP Report"
},
"category" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218533",
"display" : "ICH M11 Protocol Section 4 TRIAL DESIGN"
}
],
"text" : "section4-trial-design"
}
],
"subject" : [
{
🔗 "reference" : "ResearchStudy/568025",
"type" : "ResearchStudy",
"display" : "M11ResearchStudy Template"
}
],
"date" : "2026-05-30T17:31:51.733Z",
"author" : [
{
"display" : "Brian S. Alper, MD, MSPH"
}
],
"title" : "M11 Report Section 4 (Trial Design) for M11ResearchStudy Template",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "derived-from",
"targetReference" : {
🔗 "reference" : "ResearchStudy/568025",
"type" : "ResearchStudy",
"display" : "M11ResearchStudy Template"
}
},
{
"type" : "cite-as",
"targetMarkdown" : "M11 Report Section 4 (Trial Design) for M11ResearchStudy Template [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 568046. Revised 2026-05-30. Available at: https://fevir.net/resources/Composition/568046. Computable resource at: https://fevir.net/resources/Composition/568046#json."
}
],
"section" : [
{
"title" : "Trial Design",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218533",
"display" : "ICH M11 Protocol Section 4 TRIAL DESIGN"
}
],
"text" : "section4-trial-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No text is intended here (heading only).]</div>"
},
"section" : [
{
"title" : "Description of Trial Design",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218534",
"display" : "ICH M11 Protocol Section 4.1 Description of Trial Design"
}
],
"text" : "section4.1-description-of-trial-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Describe the overall trial design and intervention model (e.g., single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (e.g., placebo, active comparator, low dose, external, standard of care, sham procedure, or none [uncontrolled]). If there are any key aspects of the investigational trial intervention that inform the selection of the intervention model, this should be described. If applicable, indicate other design characteristics (e.g., superiority, noninferiority, dose escalation, or equivalence). If the trial will have an adaptive or novel design (e.g., the trial will be conducted under a master protocol), provide a summary of these design aspects. If applicable, describe within-trial transition rules, e.g., transitions involving cohorts or trial parts. Dose escalation or dose-ranging details should also be described. Describe the trial duration with reference to Section 1.2 Trial Schema. Explain what the overall duration for an individual participant is anticipated to be and why, including the sequence and duration of trial periods (e.g., screening, run-in, randomisation, treatment [fixed dose/titration], follow-up/washout periods). Where applicable, include discussion of sentinel dosing (or lack thereof), dose escalation, and cohort expansion. If dose modification decisions are dependent upon review by a committee, include details in Section 11.4 Committees. State the method of assignment to trial intervention the level and method of blinding that will be used with reference to Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding. Describe any other important aspects of the design, e.g.: • geographic scope of trial (e.g., single-centre, multi-centre, or multi-centre and multi-national) • use of decentralised processes, tools, or features in the trial • planned use of a Data Monitoring Committee, or similar review group and cross reference Section 11.4 Committees, for details • whether an interim analysis is planned; if so, refer to details in Section 10.9 Interim Analyses • any planned extension trial, long-term follow-up/registry, planned future use of samples or data, or post-trial sample analysis or other data-related activities]</div>"
},
"section" : [
{
"title" : "Stakeholder Input into Design",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218535",
"display" : "ICH M11 Protocol Section 4.1.1 Stakeholder Input into Design"
}
],
"text" : "section4.1.1-stakeholder-input-into-design"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any stakeholder (for example, patient, healthcare professional and patient advocacy groups) involvement in the design of the trial and any suggestions implemented.]</div>"
}
}
]
},
{
"title" : "Rationale for Trial Design",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218536",
"display" : "ICH M11 Protocol Section 4.2 Rationale for Trial Design"
}
],
"text" : "section4.2-rationale-for-trial-design"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[Enter overall rationale for trial design, if not using below optional subheadings.]</p></div>"
},
"section" : [
{
"title" : "Rationale for Estimand(s)",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218537",
"display" : "ICH M11 Protocol Section 4.2.1 Rationale for Estimand(s)"
}
],
"text" : "section4.2.1-rationale-estimands"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[When estimands are associated with the Primary and Secondary Objectives described in Section 3 Trial Objectives and Associated Estimands, provide a rationale for the estimand(s) not described elsewhere in the document. This should include a rationale that the selected endpoint(s) are clinically relevant and provide a reliable and valid measurement of the intended intervention effect. It should also include a rationale for the selected strategies for handling intercurrent events.]</div>"
}
},
{
"title" : "Rationale for Intervention Model",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218538",
"display" : "ICH M11 Protocol Section 4.2.2 Rationale for Intervention Model"
}
],
"text" : "section4.2.2-rationale-intervention-model"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a rationale for the trial intervention model described in Section 4.1 Description of Trial Design with a cross reference to Section 6.2 Rationale for Investigational Intervention Dose and Regimen. Rationale for choice of comparator, if applicable, should be described separately in Section 4.2.5 Rationale for Control Type. A rationale for the choice of trial population should be described separately in Section 5.1 Description of Trial Population and Rationale.]</div>"
}
},
{
"title" : "Rationale for Control Type",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218539",
"display" : "ICH M11 Protocol Section 4.2.3 Rationale for Control Type"
}
],
"text" : "section4.2.3-rationale-comparator"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, provide a rationale for the type and choice of control selected for the trial (e.g., placebo, active drug, combination, external). Describe any known or potential problems associated with the control group selected in light of the specific disease and intervention(s) being studied. If comparators will differ by region, describe. The rationale for dose/dose regimen is explained in Section 6.2 Rationale for Investigational Trial Intervention Dose and Regimen.]</div>"
}
},
{
"title" : "Rationale for Trial Duration",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218540",
"display" : "ICH M11 Protocol Section 4.2.4 Rationale for Trial Duration"
}
],
"text" : "section4.2.4-rationale-duration"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Provide a rationale that the trial duration is appropriate for a reliable and relevant evaluation of the trial intervention per the trial objective(s).]</div>"
}
},
{
"title" : "Rationale for Adaptive or Novel Trial Design",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218541",
"display" : "ICH M11 Protocol Section 4.2.5 Rationale for Adaptive or Novel Trial Design"
}
],
"text" : "section4.2.5-rationale-adaptive"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, provide a rationale for the use of an adaptive or novel design.]</div>"
}
},
{
"title" : "Rationale for Interim Analysis",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218542",
"display" : "ICH M11 Protocol Section 4.2.6 Rationale for Interim Analysis"
}
],
"text" : "section4.2.6-rationale-interim-analysis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, provide a rationale for any interim analysis planned with respect to its purpose (for example, stopping the trial early for efficacy or futility) and timing.]</div>"
}
},
{
"title" : "Rationale for Other Trial Design Aspects",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218543",
"display" : "ICH M11 Protocol Section 4.2.7 Rationale for Other Trial Design Aspects"
}
],
"text" : "section4.2.7-rationale-other-aspects"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Discuss rationale for any additional aspects of the design not addressed above.]</div>"
}
}
]
},
{
"title" : "Trial Stopping Rules",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218544",
"display" : "ICH M11 Protocol Section 4.3 Trial Stopping Rules"
}
],
"text" : "section4.3-trial-stopping-rules"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any trial-specific stopping rules, including guidance on when the trial should be stopped for safety reasons, when a cohort or dose escalation should be terminated, and/or when a given treatment arm should be terminated. If applicable, describe any rules that may result in a temporary pause of dosing and/or enrollment into the trial and criteria for restarting enrollment. Ensure that the trials stopping rules are aligned with the specifications that are described in Section 10.9 for Interim Analyses.]</div>"
}
},
{
"title" : "Start of Trial and End of Trial",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218545",
"display" : "ICH M11 Protocol Section 4.4 Start of Trial and End of Trial"
}
],
"text" : "section4.4-start-and-end"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Define key timepoints in the trial, including trial start and end definitions (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant’s last trial assessment has occurred). Consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment). If appropriate, provide a cross reference to Section 11.11 Early Site Closure.]</div>"
}
},
{
"title" : "Access to Trial Intervention After End of Trial",
"code" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C218546",
"display" : "ICH M11 Protocol Section 4.5 Access to Trial Intervention After End of Trial"
}
],
"text" : "section4.5-access-after-trial"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[If applicable, describe any possibilities for access to trial intervention, if any, beyond completion of the trial. Planned extension trials, if described in Section 4.1 Description of Trial Design, do not need to be repeated in this section.]</div>"
}
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-06-02
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change